SCHEMBL25044591

SCHEMBL25044591

O=C(Cn1c(Cl)nc(-c2ccc(F)cc2)c1-c1ccncc1)N1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK3 Q9Y572 1/20 0.52
MAPK14 Q16539 14/20 0.47
MAPK11 Q15759 5/20 0.43
MAPK13 O15264 4/20 0.43
MAPK12 P53778 4/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
GRIA1 P42261 1/20 0.41
NAMPT P43490 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
FGFR1 P11362 1/20 0.39
FRK P42685 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29974820 0.92 MAPK14 (0.46) RIPK3MAPK14MAPK11
SCHEMBL28878621 0.89 MAPK14 (0.49) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL25043409 0.88 RIPK3 (0.52) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL23410499 0.88 MAPK14 (0.53) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL23410438 0.88 RIPK3 (0.46) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL30232556 0.86 RIPK3 (0.50) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL30232366 0.85 RIPK3 (0.49) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL23410552 0.83 GRIA1 (0.51) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL23410260 0.83 MAPK14 (0.47) RIPK3MAPK14MAPK11MAPK13MAPK12
SCHEMBL23410600 0.81 MAPK14 (0.46) RIPK3MAPK14MAPK11MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230052017-A1 New compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2023-02-16 US disclosed
US-20230052017-A1 New compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2023-02-16 US disclosed
CN-115151256-A Novel compounds for the treatment of diseases associated with DUX expression FACIO知识产权有限公司 2022-10-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230052017-A1 New compounds for treatment of diseases related to DUX4 expression SMN1; SMN2, UTRN, DDX21 RIPK3 3338/4885MAPK14 4274/4885MAPK11 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.